Recent Updates
Recently added Catalysts
SVRA Negative Sentiment Score: 25/100

Savara Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 7, 2025 to Discuss Your Rights – SVRA

Key Takeaway: Savara Inc. is currently involved in a class action securities fraud lawsuit filed by Levi & Korsinsky, LLP. The lawsuit centers on allegations that the company made misleading statements regarding its treatment, MOLBREEVI, for pulmonary alveolar proteinosis. Plaintiffs claim that Savara did not disclose critical information affecting the likelihood of FDA approval and the company’s timeline for submission. Investors affected by this issue have until November 7, 2025, to seek recovery and potentially serve as lead plaintiffs in the case.

Market Sentiment Analysis

CONCERNS & RISKS

  • Savara Inc. is facing a class action lawsuit alleging securities fraud.
  • The lawsuit claims that the company made false statements regarding the approval of its drug, MOLBREEVI.
  • The allegations suggest a delay in regulatory approval may require Savara to raise additional capital.

Full Press Release Details

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team:
SVRA investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) MOLBREEVI BLA, the treatment of pulmonary alveolar proteinosis, lacked sufficient information regarding MOLBREEVI’s chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (iv) delay in MOLBREEVI’s regulatory approval increased the likelihood that the Company would need to raise additional capital; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Savara Inc. during the relevant time frame, you have until November 7, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the class action lawsuit about Savara Inc.?

The lawsuit addresses alleged securities fraud affecting Savara Inc. investors.

What are the key dates related to the lawsuit?

The lawsuit covers events from March 4, 2024, to May 23, 2025.

How can I participate in the Savara Inc. lawsuit?

You can request to be a lead plaintiff until November 7, 2025.

Is there a cost to join the class action lawsuit?

No, class members may receive compensation without any costs or fees.

Who should I contact for more information?

Contact Joseph E. Levi at jlevi@levikorsinsky.com or call (212) 363-7500.

Last updated: Sep 16, 2025